Rethinking How America Treats Opioid Addiction

Cato Podcast40mMay 5, 2026

Get the full intelligence

Search transcripts, export clips, track mentions, and explore all topics from “Rethinking How America Treats Opioid Addiction” inside PodZeus.

AI-Generated Summary

In this powerful episode of the Cato Podcast, host Jeff Miron speaks with Helen Redmond, a Harlem-based filmmaker, clinical social worker, and senior editor at Filter, about her new book *Liquid Handcuffs*, which critically examines the U.S. opioid treatment program (OTP) system. Redmond argues that methadone clinics—often called opioid treatment programs—are better described as 'opioid treatment prisons' due to their deeply carceral structure, including supervised dosing, mandatory urine tests, and strict control over medication access. She traces the origins of this system to the Nixon administration, revealing how it was historically used as a racially targeted crime control mechanism, disproportionately affecting Black urban communities under the guise of public health. The episode delves into the role of the DEA in policing treatment, the stigmatization of medication-assisted treatment, and the systemic barriers that prevent equitable access—such as NIMBYism, profit-driven clinics, and the lack of enforcement of federal guidelines allowing take-home doses. Despite some progress during the pandemic, Redmond emphasizes that real reform requires decoupling treatment from law enforcement, expanding prescriber access beyond OTPs, and integrating methadone into mainstream healthcare, as done in Canada, the UK, and Australia—though even those systems retain significant surveillance and stigma. The conversation culminates in a call for abolition of the current OTP model and a vision of humane, accessible, and dignified care. Key takeaways include: 1) The OTP system is rooted in racialized criminalization and should be reimagined as a public health model; 2) The DEA’s role in treatment undermines medical ethics and deters providers; 3) Take-home medication policies remain inconsistent due to clinic discretion and financial incentives; 4) Expanding access to methadone prescribing beyond OTPs—through primary care, pharmacies, and harm reduction centers—is essential for equity; 5) Even 'successful' international models still involve surveillance, highlighting that true liberation requires more than access—it demands dignity. The episode concludes with a strong advocacy for systemic change to end the cycle of control and punishment in addiction treatment.

Key Takeaways
1

Methadone clinics function as 'opioid treatment prisons' due to extreme surveillance, power imbalances, and punitive rules that violate medical ethics.

2

The OTP system originated in the Nixon era as a racially targeted crime control strategy, not a public health initiative.

3

The DEA’s involvement in treatment creates a chilling effect on providers, discouraging prescribing due to fear of scrutiny and legal action.

4

Take-home medication policies are inconsistently implemented because clinics have financial incentives to maintain daily visits.

5

True reform requires integrating methadone into mainstream healthcare, expanding prescriber access beyond OTPs, and ending the criminalization of addiction.

Chapters
0:00
2 min

Introducing Helen Redmond and the Core Thesis

I call them opioid treatment prisons... because staff control access to your medication. You don't control access to it. You're never 100% in control of your medication.

Highlight
2:00
3 min

The Carceral Nature of Methadone Clinics

They control your movements. They control everything that you do. And staff in clinics do as well.

Highlight
5:00
5 min

Historical Roots: Nixon, Race, and Crime Control

If we can associate black people with heroin and we can associate cannabis with the hippies, we can really disrupt their communities.

Highlight
10:00
5 min

The DEA’s Role in Medical Treatment

The episode critiques the DEA’s involvement in prescribing and monitoring methadone and buprenorphine, highlighting how their presence normalizes policing within healthcare and deters providers from prescribing.

15:00
5 min

The Myth of Buprenorphine as a 'White' Treatment

Redmond discusses how buprenorphine was historically positioned as suitable for white, middle-class patients, while methadone was seen as appropriate for the urban underclass—revealing deep racialized assumptions in treatment access.

High-Impact Quotes
If we can associate black people with heroin and we can associate cannabis with the hippies, we can really disrupt their communities.
Helen Redmond7:59
Viral: 95.0
I call them opioid treatment prisons... because staff control access to your medication. You don't control access to it. You're never 100% in control of your medication.
Helen Redmond1:31
Viral: 90.0
The DEA, we have to get them out of treatment. And until we do, you know, the lives of health care providers are going to be really difficult.
Helen Redmond15:58
Viral: 88.0
Speakers

Host

Jeff Miron

Guest

Helen Redmond
Topics Discussed
Opioid Treatment Programs95%Racialized Drug Policy90%Methadone Clinic Surveillance88%Medication-Assisted Treatment Access87%DEA's Role in Healthcare85%Abstinence-Only Treatment Models75%International Treatment Systems70%Harm Reduction and Overdose Prevention65%
People & Brands

Helen Redmond

person

25xPositive

Methadone

product

22xNeutral

Jeff Miron

person

18xNeutral

Drug Enforcement Administration

organization

15xNeutral

Buprenorphine

product

10xPositive

Nixon administration

organization

8xNegative

Substance Abuse and Mental Health Services Administration

organization

7xNegative

Fentanyl

product

6xNeutral

Liquid Handcuffs

book

5xPositive

Canadian healthcare system

other

4xPositive

Get the full intelligence

Search transcripts, export clips, track mentions, and explore all topics from “Rethinking How America Treats Opioid Addiction” inside PodZeus.

Start discovering podcast insights today

Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.

No credit card required • 7-day trial • Cancel anytime